TGTX
Companies
NASDAQ
Tg Therapeutics Inc.
Health Care
$35.17
+$5.06 (+16.83%)
Price Chart
Overview
About TGTX
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.
Market Cap
$2.4B
Volume
99.4M
Avg. Volume
117.3M
P/E Ratio
36.628864
Dividend Yield
0.00%
Employees
270.0
Company Information
Risk & Correlation Analysis
Market Correlation
1.38
High Correlation
Volatility
High (0.67)
Relative to market
Macro Factor Sensitivities
Interest Rates
Medium Sensitivity
Inflation
High Sensitivity
GDP Growth
Low Sensitivity
Liquidity
Low Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
High Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, TGTX shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$2.4B
Volume99.4M
P/E Ratio36.63
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
November 4, 2024Related Securities
Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025